Clinical Trial: NCT04606771
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-07-30 |
Study Overview
Brief Summary
This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.
Official Title
A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Osimertinib + Savolitinib
- Drug: Savolitinib + Placebo
Other Study ID Numbers
- D5084C00009
Start Date (Actual)
2020-09-28
Primary Completion Date (Actual)
2022-12-21
Study Completion Date (Estimated)
2027-03-15
Enrollment (Actual)
30
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | AstraZeneca |
| Information Provided By: | AstraZeneca |
| Last Update Posted: | 2026-07-30 |
Study Overview
Brief Summary
This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.
Official Title
A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib
Conditions
Non-Small Cell Lung Cancer
Intervention / Treatment
- Drug: Osimertinib + Savolitinib
- Drug: Savolitinib + Placebo
Other Study ID Numbers
- D5084C00009
Start Date (Actual)
2020-09-28
Primary Completion Date (Actual)
2022-12-21
Study Completion Date (Estimated)
2027-03-15
Enrollment (Actual)
30
Study Type
Interventional
Phase
Phase 2